BR112012015682A2 - composição transportadora. - Google Patents

composição transportadora.

Info

Publication number
BR112012015682A2
BR112012015682A2 BR112012015682A BR112012015682A BR112012015682A2 BR 112012015682 A2 BR112012015682 A2 BR 112012015682A2 BR 112012015682 A BR112012015682 A BR 112012015682A BR 112012015682 A BR112012015682 A BR 112012015682A BR 112012015682 A2 BR112012015682 A2 BR 112012015682A2
Authority
BR
Brazil
Prior art keywords
carrier composition
present
formulated
formulation
relatively high
Prior art date
Application number
BR112012015682A
Other languages
English (en)
Inventor
Gaetano Giancito
james cottrell Jeremy
El-Tamimy Mahmoud
john kennedy Nicholas
David Gavina Paul
Original Assignee
Phosphagenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phosphagenics Ltd filed Critical Phosphagenics Ltd
Publication of BR112012015682A2 publication Critical patent/BR112012015682A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

composição transportadora. uma composição transportadora da presente invenção compreende um composto de fosfato de um agente de transferência de elétrons e uma concentração relativamente elevada de um solvente polar prótico. um composto biologicamente ativo pode ser formulado com uma composição transportadora da presente invenção para proporcionar uma formulação.
BR112012015682A 2009-12-23 2010-12-22 composição transportadora. BR112012015682A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28950709P 2009-12-23 2009-12-23
PCT/AU2010/001719 WO2011075775A1 (en) 2009-12-23 2010-12-22 Carrier composition

Publications (1)

Publication Number Publication Date
BR112012015682A2 true BR112012015682A2 (pt) 2019-09-24

Family

ID=44194821

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012015682A BR112012015682A2 (pt) 2009-12-23 2010-12-22 composição transportadora.

Country Status (16)

Country Link
US (2) US20120202780A1 (pt)
EP (1) EP2516011B1 (pt)
JP (1) JP5841062B2 (pt)
KR (1) KR20120107963A (pt)
CN (1) CN102686279B (pt)
AU (1) AU2010336018B2 (pt)
BR (1) BR112012015682A2 (pt)
CA (1) CA2785242A1 (pt)
ES (1) ES2643643T3 (pt)
IL (1) IL220490A0 (pt)
MX (1) MX2012007412A (pt)
NZ (1) NZ600773A (pt)
RU (1) RU2577233C2 (pt)
SG (1) SG181808A1 (pt)
WO (1) WO2011075775A1 (pt)
ZA (1) ZA201204369B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
US9561243B2 (en) 2011-03-15 2017-02-07 Phosphagenics Limited Composition comprising non-neutralised tocol phosphate and a vitamin A compound
JP6449554B2 (ja) * 2014-03-30 2019-01-09 小林製薬株式会社 外用医薬組成物
RU2742650C2 (ru) * 2015-12-09 2021-02-09 Фосфейдженикс Лимитед Фармацевтический состав
AU2016367708B2 (en) * 2015-12-09 2022-07-14 Phosphagenics Limited Pharmaceutical formulation
WO2017143360A1 (en) * 2016-02-18 2017-08-24 Drabinsky Michael Earl Treatment for microbial borne illness
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법
KR20240068806A (ko) * 2022-10-28 2024-05-20 주식회사 오가시스 κ-오피오이드 수용체의 아고니스트를 포함하는 피부 미백용 조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657526B1 (fr) * 1990-01-31 1994-10-28 Lvmh Rech Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues.
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
WO2002040033A1 (en) * 2000-11-14 2002-05-23 Vital Health Sciences Pty Ltd Formulation containing phosphate derivatives of electron transfer agents
MXPA04000654A (es) * 2001-07-27 2004-03-19 Vital Health Sciences Pty Ltd Terapia dermica usando derivados de fosfato de agente de transferencia de electrones.
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
AU2002950713A0 (en) * 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
FR2846651B1 (fr) * 2002-10-30 2006-06-16 Rhodia Polyamide Intermediates Procede de fabrication d'acides carboxyliques
ATE534384T1 (de) * 2003-01-17 2011-12-15 Vital Health Sciences Pty Ltd Verbindungen mit proliferationshemmenden eigenschaften
EP1893159B1 (en) * 2005-06-17 2015-09-30 Vital Health Sciences Pty Ltd. A carrier comprising one or more di- and/or monophosphate derivatives of electron transfer agents
RU2373957C2 (ru) * 2006-10-13 2009-11-27 Александр Метталинович Тишин Носитель для лекарственных средств и биологически активных веществ для лечения и диагностики и применение его для создания лекарственных средств и способа регулируемой управляемой доставки лекарственного средства или биологически активного вещества с регулируемой десорбцией его

Also Published As

Publication number Publication date
EP2516011A1 (en) 2012-10-31
NZ600773A (en) 2014-04-30
WO2011075775A1 (en) 2011-06-30
IL220490A0 (en) 2012-08-30
CA2785242A1 (en) 2011-06-30
US20120202780A1 (en) 2012-08-09
US20160331838A1 (en) 2016-11-17
JP5841062B2 (ja) 2016-01-06
JP2013515012A (ja) 2013-05-02
CN102686279A (zh) 2012-09-19
MX2012007412A (es) 2012-07-17
EP2516011B1 (en) 2017-07-12
AU2010336018B2 (en) 2015-10-01
KR20120107963A (ko) 2012-10-04
EP2516011A4 (en) 2013-07-03
SG181808A1 (en) 2012-07-30
AU2010336018A1 (en) 2012-07-05
RU2012126143A (ru) 2014-01-27
ES2643643T3 (es) 2017-11-23
ZA201204369B (en) 2013-02-27
RU2577233C2 (ru) 2016-03-10
CN102686279B (zh) 2015-07-15

Similar Documents

Publication Publication Date Title
BR112012015682A2 (pt) composição transportadora.
BR112012019508A2 (pt) composição de veículo
BR112012022774A2 (pt) Composição sólida compreendendo primeira e segunda dispersões sólidas amorfas
BR112013006341A2 (pt) formulações agrícolas líquidas com estabilidade aperfeiçoada
CL2015001984A1 (es) (divisional de la sol. 1567-2013) combinaciones de principios activos que comprenden piridiletilbenzamidas y otros principios activos.
CO6260093A2 (es) Derivados de sulfonil amida para el tratamiento del crecimiento celular anormal
AR068195A1 (es) Composiciones y metodos para el tratamiento de semillas
PE20160854A1 (es) Inhibidores de nitrificacion disenados para fertilizantes a base de estiercol y urea
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112012018761A2 (pt) estruturas para prevenir fixação de microorganismos
BR112012026801A2 (pt) conjugados de pirrolobenzodiazepina direcionados.
BR112014004460A2 (pt) material polimérico para um recipiente isolado
RS54815B1 (sr) Supstanca koja sadrži antibiotik i disperzant
BR112014000178A2 (pt) composições tópicas
UY33832A (es) Inhibidores de la faah.
BR112015013437A2 (pt) composição de revestimento; e lata ou embalagem utilizável para acondicionar alimentos
CA2885848C (en) Non-irritating lubricant compositions with active sensorial agents
BR112019024760A2 (pt) uso de dodecano, composição inoculante líquida, semente de planta revestida, kit, e, método.
EA201390612A1 (ru) Биоразлагаемая композиция для доставки лекарственного средства
SV2013004451A (es) Compuestos y su uso
BR112012007798A2 (pt) microcápsulas estáveis e composição para aplicação tópica e método para a preparação de microcápsulas
AR072685A1 (es) Composicion topica para el tratamiento de queratosis actinica
BR112012028037A2 (pt) formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit
MX344324B (es) Endoprotesis que contiene un recubrimiento de substancia activa.
AR082771A1 (es) Composicion de formulacion agroquimica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.